Therefore, at the time of the withdrawal, the CHMP’ s view was that a benefit of Tygacil had not been sufficiently demonstrated and any benefits did not outweigh the identified risks.
Por consiguiente, en el momento de la retirada de la solicitud, el CHMP opinaba que el beneficio de Tygacil no había quedado suficientemente demostrado y que no superaba los riesgos identificados.